30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Matt Pauls

Track

Insider profile

Currently holds positions in Strongbridge Biopharma plc, Zyla Life Sciences and Savara Inc

Performance

Overall performance
2.8
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -2% 8.2% 15.1%
Success rate 21% 68% 82%
Transactions
8 62% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 331%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Chief Executive Officer, Director Strongbridge Biopharma plc Aug. 1, 2014 -
Director Zyla Life Sciences Jan. 31, 2019 -
Independent Director Savara Inc Nov. 2, 2015 -
Chief Commercial Officer Insmed Inc April 1, 2013 - Dec. 1, 2014
Matt Pauls's trades of Channel Therapeutics Corp's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-06 2026-04-02
PlS Planned sale
86,320 +37.0%
38.70
US$1,751,576 		86,320 +37.0% 38.70 US$1,751,576
2026-04-06 2026-04-02
PlS Planned sale
36,476 +31.5%
452.31
US$3,702,188 		36,476 +31.5% 452.31 US$3,702,188
2025-03-31 2025-03-28
S Sale
28,695 -43.4%
349.44
US$4,976,328 		28,695 -43.4% 349.44 US$4,976,328
2025-03-28 2025-03-28
PrS Proposed sale
5,937
67.39
US$400,094 		5,937 67.39 US$400,094
2024-12-16 2024-12-16
US Savara Inc (SVRA)
PrS Proposed sale
54,702
3.31
US$180,800 		54,702 3.31 US$180,800
2024-12-16 2024-12-16
US Savara Inc (SVRA)
S Sale
54,702 -3.4%
3.31
US$180,828 		54,702 -3.4% 3.31 US$180,828
2023-12-29 2023-12-28
US Savara Inc (SVRA)
S Sale
84,000 -6.1%
4.71
US$395,900 		84,000 -6.1% 4.71 US$395,900
2023-12-28 2023-12-28
US Savara Inc (SVRA)
PrS Proposed sale
84,000
4.74
US$398,000 		84,000 4.74 US$398,000
2021-12-08 2021-12-08
US Savara Inc (SVRA)
B Purchase
6,500 +1.7%
1.06
US$6,889 		6,500 +1.7% 1.06 US$6,889
2021-12-02 2021-12-02
US Savara Inc (SVRA)
B Purchase
10,000 +2.7%
1.10
US$10,954 		10,000 +2.7% 1.10 US$10,954
2021-11-22 2021-11-19
US Savara Inc (SVRA)
B Purchase
2,150 +0.6%
1.07
US$2,290 		2,150 +0.6% 1.07 US$2,290
2021-11-22 2021-11-19
US Savara Inc (SVRA)
B Purchase
10,000 +2.8%
1.11
US$11,100 		10,000 +2.8% 1.11 US$11,100
2021-11-22 2021-11-18
US Savara Inc (SVRA)
B Purchase
10,000 +2.9%
1.10
US$11,000 		10,000 +2.9% 1.10 US$11,000
2021-04-19 2021-04-19
US Savara Inc (SVRA)
PP Planned purchase
27,400 +9.8%
1.82
US$49,871 		27,400 +9.8% 1.82 US$49,871
2021-03-22 2021-03-22
US Savara Inc (SVRA)
PP Planned purchase
24,100 +9.4%
2.07
US$49,938 		24,100 +9.4% 2.07 US$49,938
2021-02-23 2021-02-22
US Savara Inc (SVRA)
PP Planned purchase
28,700 +12.6%
1.74
US$50,038 		28,700 +12.6% 1.74 US$50,038